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Summary The current overview of zonisamide use and effectiveness is based on
both a long-term prospective postmarketing survey and current zonisamide use at the
Saitama Medical College, Department of Neuropsychiatry. Survey data, which were
collected from individual physicians and 23 survey groups throughout Japan, assessed
the effectiveness of zonisamide in 1631 patients. Zonisamide was highly effective for
treating partial seizures, with 70% of patients reporting improvement. More than half
of patients with generalized seizures (58%) and half of patients with myoclonic and
atypical absence seizures showed improvement with zonisamide treatment. Among
the different epileptic syndromes, zonisamide was highly effective in treating gener-
alized idiopathic epilepsy (≥78% improvement) and partial epilepsy (≥58% improve-
ment). However, only 28% of patients with West syndrome or Lennox-Gastaut syn-
drome showed improvement. Among 60 outpatients treated with zonisamide at our
facility as of October 1998, most had partial seizures or generalized seizures sub-
sequent to partial seizures. The majority of patients received zonisamide in com-
bination with other antiepilepsy drugs. Patients receiving zonisamide monotherapy
showed greater improvement than did patients receiving polytherapy. We conclude
that zonisamide is highly effective for partial seizures and generalized seizures, and
that there appears to be no decrease in efﬁcacy with long-term use.
© 2004 Published by Elsevier Ltd on behalf of BEA Trading Ltd.
Introduction
Zonisamide has been used in the treatment of
epilepsy in Japan since it was ﬁrst marketed in 1989
under the trade name of Excegran®. We wish to
present the current status of zonisamide in Japan,
especially with regard to efﬁcacy of this drug,
from two perspectives. One is from postmarketing
prospective study data, and the other is from our
experience in the Department of Neuropsychiatry
at Saitama Medical School.
*Corresponding author. Tel.: +81 49 276 1106;
fax: +81 49 276 1622.
E-mail address: XLF05564@niftyserve.or.jp (T. Yamauchi).
Postmarketing study
Objectives and methods
In order to assess the efﬁcacy and safety of
long-term administration of zonisamide, patients
with partial and generalized epilepsy were enrolled
in a postmarketing prospective study and observed
for 1—3 years.
Newly diagnosed patients most often received
zonisamide as monotherapy. When zonisamide
was added to therapy with other antiepilepsy
drugs (AEDs), the dosage of the other AEDs was
reduced if seizures ceased. Doses in pediatric
patients ranged from less than 2mg/kg per day
to more than 10mg/kg per day, and about 70%
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Table 1 Examination schedule for patients.
Seizure times
(4 weeks)
Laboratory
examination
EEG Side effects
Before administration • • • Throughout
observation
period
4th week •
8th week •
12th week • •a
16th week • •a
20th week •
24th week • •
6—9 months •
1 year • • •b
1+ year after
administration
• Every 4—6 months
a Either the 12th week or the 16th week.
b Once every 9 months to 1 year.
of patients were given zonisamide at 2—8mg/kg
per day. Doses in adults varied from less than
100mg/day to more than 500mg/day, and about
80% of patients received 200—400mg/day. Eval-
uations were performed by the physicians of 23
survey research groups and by other individually
participating physicians. Patient observations and
examinations were carried out at the ﬁrst, second,
and the third years of zonisamide administration
according to a predetermined schedule depicted in
Table 1.
Discontinuation
The efﬁcacy of zonisamide was analyzed with 1239
patients. At the end of their ﬁrst year of zonisamide
therapy, 1184 patients completed questionnaires.
The following year, 680 questionnaires were col-
lected from patients who continued to receive
zonisamide. Three hundred ninety-two question-
naires were completed by patients who received
zonisamide for more than 2 years (Table 2). There
were differences in numbers between patients
analyzed and patients who presented ﬁrst-year
questionnaires because 55 of the 680 patients who
received zonisamide for more than 1 year did not
submit their ﬁrst-year questionnaires. There was
a 16.2% discontinuation rate during the ﬁrst year.
Reasons cited included insufﬁcient therapeutic ef-
fect (8.7%), side effects (6.2%), or both (1.4%).
However, in the second year the discontinuation
rate decreased to 7.2%, and in the third year it was
2.3%.
These results demonstrate that zonisamide efﬁ-
cacy becomes evident at an early stage of treat-
ment. Only patients responding to zonisamide
treatment were continued on the drug. Further-
more, zonisamide efﬁcacy was often associated
with a low occurrence of side effects, indicating the
possibility of continuous, long-term administration.
Table 2 Dropouts and terminations from the zon-
isamide long-term postmarketing study.
Number of
patients (%)
First year
Started 1184
Continued 992 (84.0)
Dropout/discontinuation 192 (16.2)
Reason
Poor effect 103 (8.7)
Adverse events 73 (6.2)
Poor effect/adverse events 16 (1.4)
Second year
Started 680
Continued 631 (92.8)
Dropout/discontinuation 49 (7.2)
Reason
Poor effect 40 (6.3)
Adverse events 8 (1.3)
Poor effect/adverse events 1 (0.2)
Third year
Started 392
Continued 383 (97.7)
Dropout/discontinuation 9 (2.3)
Reason
Poor effect 7 (1.8)
Adverse events 2 (0.5)
Poor effect/adverse events 0
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Evaluation of efﬁcacy
Efﬁcacy was evaluated by reduction of seizure
frequency or overall improvement. Reduction of
seizure frequency was classiﬁed as follows: seizure
free, complete suppression of seizures; marked
improvement, >75% decrease in seizures; im-
proved, ≥50% decrease in seizures; no change,
<50% decrease in seizures; worsening, an increase
in seizures. Overall improvement was evaluated by
the physician in charge based on the assessment of
reduction of seizure frequency, EEG ﬁndings (im-
proved, unchanged, or worse), and epileptic symp-
toms, and then classiﬁed as follows: markedly im-
proved, improved, slightly improved, unchanged,
and worsening.
Zonisamide efﬁcacy by seizure type
As shown in Table 3, partial seizures were com-
pletely suppressed in 43.4% of 1172 patients, and
efﬁcacy was improved or better in 70.5% of the
patients. Improved rates were similar among pa-
tients with simple partial seizures, complex partial
seizures, and secondarily generalized seizures (data
not shown).
Among 274 patients with generalized seizures,
122 were classiﬁed with tonic—clonic seizures, 128
with tonic seizures, and 24 with clonic seizures.
Overall within this group, seizures were improved
or better than improved in 56.9% of the patients
(data not shown). Although zonisamide was less ef-
ﬁcacious in treating generalized seizures than par-
tial seizures, this efﬁcacy was still high.
On the other hand, patients with myoclonic
seizures had a seizure-free rate of 19.6%, with
51.8% rated as improved or better. Efﬁcacy against
atonic seizures was rated as improved or better
Table 3 Seizure improvement rate among patients classiﬁed by seizure type.
Seizure type (n) Patients (%)
Seizure free Markedly improved Improved No change Worse
Partial (1172) 43.4 10 17.1 23.5 6
Tonic—clonic (122) 42.6 11.5 13.9 28.7 3.3
Tonic (128) 18.8 7 17.2 43.8 13.3
Clonic (24) 62.5 0 12.5 20.8 4.2
Atonic (37) 24.3 13.5 18.9 32.4 10.8
Myoclonic (56) 19.6 14.3 17.9 46.4 1.8
Typical absence (8) 50 12.5 25 12.5 0
Atypical absence (54) 14.8 5.6 25.9 51.9 1.9
Other (30) 16.7 13.3 13.3 43.3 13.3
Total (1631) 39 9.9 17.1 27.7 6.3
in 56.7% of patients. Among eight patients with
typical absence seizures, 87.5% were rated as im-
proved or better. In patients with atypical absence
seizures, 46.3% were rated as improved or better
with zonisamide treatment.
Zonisamide efﬁcacy by epileptic syndrome
Table 4 shows the overall improvement rates
among patients classiﬁed by epileptic syndrome.
Among patients with partial epilepsy, 29.8% showed
marked improvement, and 58.2% were improved or
better. On the other hand, among patients with pri-
mary generalized epilepsy, 39.5% showed marked
improvement, and overall 78.2% were improved or
better. However, only 28.0% of patients with West
syndrome and 27.9% of Lennox-Gastaut syndrome
patients were improved or markedly improved.
Among patients with other generalized epilepsies,
41.3% were improved or markedly improved.
Patient background
Age
Overall improvement according to patient age is
shown in Table 5. Patients were grouped as ≤1, 2—
15, and ≥16 years of age. Improvement rates were
similar across all age groups.
Interaction of AED therapy and seizure type
Effects of zonisamide were analyzed by seizure
type and also by the type of zonisamide therapy
(monotherapy or polytherapy; Table 6). The zon-
isamide monotherapy group had a signiﬁcantly
higher improvement rate (deﬁned as greater than
or equal to 50% reduction in seizure frequency) than
did the polytherapy group (P < 0.01). However,
there was no difference in the improvement rates
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Table 4 Overall improvement ratea among patients classiﬁed by epileptic syndromes.
Patients (%)
Markedly improved Improved Slightly improved No change Worse
Partial epilepsy
Temporal lobe (n = 302) 22.8 27.2 16.2 28.8 5.0
Non-temporal lobe (n = 485) 32.2 29.7 14.4 20.0 3.7
Other partial (n = 103) 38.8 26.2 15.5 15.5 3.9
Subtotal (n = 890) 29.8 28.4 15.2 22.4 4.2
Generalized epilepsy
Generalized idiopathic (n = 119) 39.5 38.7 6.7 15.1 0
West syndrome (n = 25) 12.0 16.0 16.0 40.0 16.0
Lennox-Gastaut syndrome (n = 79) 11.4 16.5 12.7 51.9 7.6
Other generalized (n = 126) 15.9 25.4 19.8 32.5 6.3
Subtotal (n = 349) 22.6 27.2 13.5 31.5 5.2
Total (n = 1239) 27.8 28.1 14.7 25.0 4.4
a Improvement rate determined by physician in charge.
Table 5 Overall improvement rate by patient age.
Age, years (n) Patients (%)
Markedly improved Improved Slightly improved No change Worse
≤1 (35) 21.1 28.6 8.6 37.1 8.6
2—15 (739) 32.5 27.6 13.4 22.3 3.9
≥16 (465) 21.1 28.8 16.8 28.4 4.9
Table 6 Seizure improvement in patients by seizure type and AED therapy.
AED therapy Patients with more than 50% reduction in seizure frequency (%)
Partial seizures Generalized seizures Total
ZNS monotherapy 92.9 (326) 91.2 (68) 92.6 (394)
Polytherapy 61.8 (846) 48.6 (370) 48.6 (370)
P < 0.01 (monotherapy vs. polytherapy).
between patients with partial seizures and patients
with generalized seizures. As patients who received
polytherapy, and those intractable to treatments,
are considered to have strong epileptogenesis, the
ﬁndings suggest that seizures produced by strong
epileptogenesis were poorly controlled, even with
combinations of zonisamide and other AEDs. This
suggests that a high improvement rate can be an-
ticipated when zonisamide is the ﬁrst choice of
drug to use.
Postmarketing study conclusions
From the postmarketing survey for long-term treat-
ment, the following conclusions were obtained:
1. Zonisamide was highly effective for partial
seizures, with 70.5% of patients showing im-
proved or better seizure control.
2. Among patients with generalized seizures
(tonic—clonic, tonic, or clonic), 56.9% of pa-
tients showed improved or better seizure con-
trol with zonisamide treatment.
3. For patients with myoclonic seizures or atypical
absence seizures, approximately 50% showed im-
proved or better seizure control with zonisamide
treatment.
4. When the overall improvement rate was clas-
siﬁed by epileptic syndromes, zonisamide was
found to be highly effective, showing an im-
provement rate of 58.2% in partial epilepsies
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and 78.2% in generalized idiopathic epilepsies.
However, improvement rates were lower for pa-
tients with West syndrome and Lennox-Gastaut
syndrome–—28.0 and 27.9%, respectively.
5. A greater than 50% reduction in seizure fre-
quency was observed in more than 80% of pa-
tients treated with zonisamide monotherapy.
Among patients given concomitant therapy, 60%
showed improvement.
6. Zonisamide is highly effective for seizure control
and relatively safe for long-term use.
Efﬁcacy of zonisamide based on our
experiences in the Department of
Neuropsychiatry at Saitama Medical
School
To understand how zonisamide is used for the
treatment of patients with epilepsy, we have ex-
amined numerous patients who were treated with
zonisamide in the Department of Neuropsychiatry
at the Saitama Medical School. We carried out a
retrospective study and analysis based on data col-
lected in October 1998, from 60 outpatients being
treated with zonisamide.
Patient background
Age, sex, duration of epilepsy
The study included 30 male and 30 female patients.
Ages of the 60 patients in the cohort ranged from 15
to 73 years (mean = 36.5 ± 14.8). Age at epilepsy
onset was 3—68 years (mean = 19.8 ± 13.8), and
duration of epilepsy was 1—57 years (mean = 17.5
± 12.8). In summary, our patients represented a
wide range in terms of age, age of epilepsy onset,
and duration of epilepsy.
Seizure type
Fifty-three patients had partial seizures (88.3%),
ﬁve had tonic—clonic seizures (8.3%), and two had
myoclonic seizures (3.3%). Of the patients with par-
tial seizures, 14 had simple partial seizures (26.4%)
and 39 had complex partial seizures (73.6%).
Dosage and administration of zonisamide
Ten patients were treated with zonisamide mono-
therapy. The remaining 50 patients were treated
with zonisamide in combination with other AEDs,
such as valproic acid (57.8%), phenytoin (6%), car-
bamazepine (51.1%), phenobarbital (31%), clon-
azepam (26.7%), or other drugs (6.6%). Among
those patients taking zonisamide alone, the aver-
age dose of zonisamide was 250 ± 52.7mg (range
Table 7 Seizure improvement in patients by seizure
type.
Seizure type (n) Patients number (%)
Markedly
improved
Improved No effect
Partial (49) 51 (25) 32.7 (16) 16.3 (8)
Tonic—clonic (5) 60 (3) 0 40 (2)
Myoclonic (2) 0 50 (1) 50 (1)
Total (56) 50 (28) 30.4 (17) 19.6 (11)
200—300mg). Among patients taking zonisamide
in combination with other AEDs, the average dose
of zonisamide was notably higher, 286 ± 108.8mg
(range 100—600mg).
Effect of zonisamide on seizures
Rate of seizure improvement according to
seizure type
The efﬁcacy of zonisamide was not evaluable
in four patients because they had already been
treated with zonisamide when they were referred
to our clinic and their seizures had stopped. These
patients were excluded. Among the remaining 56
patients analyzed in this study, 49 had partial
seizures, ﬁve had tonic—clonic seizures, and two
had myoclonic seizures (Table 7). Fifty percent (28
patients) were seizure free or showed marked im-
provement, 30.4% (17 patients) showed improve-
ment (50—75% decrease in seizures), and 19.6%
(11 patients) showed no change. These seizure
control rates largely reﬂect improvement among
partial seizure patients, who made up the largest
percentage of the group. However, three out of
ﬁve patients with tonic—clonic showed marked im-
provement. Of the two patients with myoclonic
seizures, one improved and one showed no change.
Furthermore, although we investigated patients
with simple and complex partial seizures, both
with or without secondary generalization, we found
no evidence of signiﬁcant differences in seizure
reduction based on the seizure type.
Relationship between efﬁcacy and the number
of AEDs
The seizure control rate was higher among those
patients using zonisamide alone (88.9% markedly
improved, 11.1% improved, 0% no effect) compared
with the group using zonisamide in combination
with other AEDs (42.6% markedly improved, 34.0%
improved, 23.4% no effect; P < 0.05). Since we
found lower efﬁcacy in the polytherapy group, we
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Table 8 Relationship between seizure improvement and number of AEDs.
AED therapy Patients (%)
Markedly improved Improved No effect P valuea
ZNS monotherapy (9) 88.9 (8) 11.1 (1) 0 —
Number of concomitant AEDs in zonisamide polytherapy
≥3 (13) 23.1 (3) 46.2 (6) 30.7 (4) N.S.
2 (16) 31.3 (5) 31.3 (5) 37.5 (6) 0.05
1 (18) 61.1 (12) 33.3 (5) 5.6 (1) 0.01
Subtotal (47) 42.6 (20) 34.0 (16) 23.4 (11) 0.05
Total 50.0 (28) 30.4 (17) 19.6 (11) —
Figures in parentheses are the number of patients.
a Differences between the monotherapy group and polytherapy groups were statistically analyzed.
investigated the relationship between zonisamide
efﬁcacy and the number of concomitant AEDs. The
results from this analysis, shown in Table 8, demon-
strate that seizure control drops as the number of
AEDs increases. These ﬁndings suggest that further
investigation is needed to understand relationships
between zonisamide dosage, the number of con-
comitant drugs, and zonisamide efﬁcacy.
Number of concomitant AEDs and zonisamide
efﬁcacy
The number of concomitant AEDs used to treat
patients in each efﬁcacy group was examined.
Markedly improved patients were treated with
an average of 1.2 AEDs; patients in the improved
group, 2.0 AEDs; and patients in the unchanged
group, 2.4 AEDs. This analysis shows that the pa-
tients in the unchanged group were taking more
AEDs compared to the other groups.
Zonisamide dosage and efﬁcacy
Relationships between the dose of zonisamide
and its effect on seizure rate were examined. We
found that the dosage of zonisamide was signif-
icantly greater for the improvement group (347
± 100.7mg), compared to the patients in the
markedly improved (250 ± 79.3mg) or unchanged
(254.5 ± 121.4mg) groups. These ﬁndings suggest
that in responsive patients, most likely those with
relatively weak epileptogenesis, seizures can be
controlled by low doses of zonisamide. In our study,
this type of patient who showedmarked response to
zonisamide was encountered in 28 of 56 cases (50%).
Relationship between plasma concentration
and administered zonisamide dose
We hypothesized that poor seizure control at high
doses of zonisamide may result from poor absorp-
tion. To conﬁrm this hypothesis, we investigated the
relationship between administered dose and plasma
concentration of zonisamide. We found that zon-
isamide concentration increased dose-dependently
(Fig. 1).
Relationship between plasma concentration of
zonisamide and number of AEDs
We then investigated the relationship between the
ratio of plasma concentration to the administered
dose of zonisamide and number of concomitant
AEDs (Fig. 2). The ratio of plasma concentration
to administered dose decreased with increasing
numbers of concomitant AEDs.
Effect of other AEDs on plasma concentration of
zonisamide
We next examined the relationship between indi-
vidual concomitant AEDs and the ratio of plasma
concentration to the administered dose of zon-
isamide (Fig. 3). Results showed that the ratio is
signiﬁcantly lower when zonisamide is adminis-
tered with PHT (P < 0.05). It also became evident
that carbamazepine, phenobarbital, valproic acid,
and clonazepam have no inﬂuence upon zonisamide
concentration.
Relationship between plasma concentration of
zonisamide and efﬁcacy
The relationship between plasma concentration
of zonisamide and efﬁcacy was then examined.
The eight patients whose seizures were unaf-
fected by zonisamide treatment had signiﬁcantly
lower plasma concentrations of zonisamide (10.2
± 8g/mL), compared with the 14 patients whose
seizures improved (19.0 ± 6.1g/mL), or the 20
patients whose seizures markedly improved (17.6
± 6.6g/mL; P < 0.05 and 0.05, respectively).
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Figure 1 Relationship between zonisamide dose and
plasma concentration. Dots and bars are the means ±
S.D.
Patients unaffected by zonisamide treatment
From the above investigation, it was evident that
dosage and plasma concentration of zonisamide
were low in those patients whose seizures were
unaffected by zonisamide treatment. Several ex-
planations may apply:
1. Low plasma concentrations of zonisamide may
be insufﬁcient to suppress epileptic seizures.
2. Combined administrations of several AEDs with
zonisamide might decrease the plasma concen-
tration of zonisamide.
3. Patients in this group have strong epileptogen-
esis; therefore seizures may not be suppressed
even by AED polytherapy.
Characteristics of three patient groups
From the data reported here, patients could be cat-
egorized into three groups:
Figure 2 Relationship between ratio of plasma zon-
isamide concentration to zonisamide dose and number of
AEDs added to zonisamide. Dots and bars are the means
± S.D.
Figure 3 Effects of other AEDs on ratio of ZNS plasma
concentration/ZNS dose in patients from the department
of neuropsychiatry. () Patients who received ZNS alone
or ZNS plus AEDs other than the AED indicated under
the columns. ( ) Patients who received ZNS plus AEDs
indicated under the columns with or without other AEDs.
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1. Those whose seizures were managed with low
zonisamide doses (250 ± 79.3mg/day). Patients
in this group were given zonisamide alone or in
combination with a few other AEDs. Seizure re-
duction rates were ≥75%.
2. Those whose seizures were controlled by higher
zonisamide doses (347.1 ± 100.7mg/day) or by
combination therapy. Seizure reduction rates
were 50% to 75%.
3. Those patients whose seizures were not sufﬁ-
ciently controlled with zonisamide monotherapy
or combined therapy, possibly because the dose
of zonisamide was not high enough, or because
drug interactions prevented attainment of ef-
fective zonisamide plasma levels.
Discussion and conclusions
Results of our investigation suggest the following
conclusions:
1. Zonisamide is a highly effective AED for partial
seizures as well as some generalized seizures,
such as tonic—clonic seizures.
2. There is no decrease in efﬁcacy and no tolerance
is evident with zonisamide treatment, even after
long-term use.
3. Good seizure control may be possible with zon-
isamide monotherapy.
4. Sufﬁcient plasma concentrations of zonisamide
are needed to control seizures in patients who
are highly resistant to treatment. When zon-
isamide is administered with other AEDs, plasma
concentration of zonisamide may not rise in
proportion to the zonisamide dose. Thus, it is
important to give doses of zonisamide sufﬁ-
cient to reach therapeutic levels while carefully
monitoring plasma concentrations.
